Retifanlimab-Dlwr: uses, dosing, side effects & brands
Retifanlimab-Dlwr is a medicine sold in the U.S. under one brand, for merkel cell carcinoma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Merkel Cell Carcinoma
- Available as
- Injectable
- Sold as
- Zynyz
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How retifanlimab-dlwr is dosed
From the FDA label for Zynyz (application BLA761334). Other retifanlimab-dlwr products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Administer ZYNYZ as an intravenous infusion over 30 minutes after dilution ( 2.3 ): For Squamous Cell Carcinoma of the Anal Canal (SCAC), in combination with carboplatin and paclitaxel, or as a single agent ( 2.1 ): 500 mg every 4 weeks, or 375 mg every 3 weeks For Merkel Cell Carcinoma (MCC) ( 2.1 ): 500 mg every 4 weeks See full prescribing information for dosage modifications for adverse reactions ( 2.2 ) and preparation and administration instructions. ( 2.3 ) 2.1 Recommended Dosage The recommended dosages of ZYNYZ are provided in Table 1. Administer ZYNYZ as an intravenous infusion after dilution, over 30 minutes, as recommended [see Dosage and Administration ( 2.3 )] . Table 1: Recommended Dosage of ZYNYZ Indication Recommended Dosage of ZYNYZ Duration of Treatment Combination Therapy Refer to the Prescribing Information for the agents administered in combination with ZYNYZ for recommended dosing information, as appropriate. Adult patients with inoperable locally recurrent or metastatic SCAC in combination with carboplatin and paclitaxel 500 mg every 4 weeks or 375 mg every 3 weeks Until disease progression, unacceptable toxicity, or up to 12 months Monotherapy Adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy 500 mg every 4 weeks or 375 mg every 3 weeks Until disease progression,…
Retifanlimab-Dlwr side effects
The following adverse reactions are described elsewhere in the labeling. Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions ( 5.1 )] Infusion-Related Reactions [see Warnings and Precautions ( 5.2 )] Complications of Allogeneic HSCT [see Warnings and Precautions ( 5.3 )] ZYNYZ in Combination with Carboplatin and Paclitaxel In patients with SCAC, the most common (≥ 20%) adverse reactions are fatigue, peripheral neuropathy, nausea, alopecia, diarrhea, musculoskeletal pain, constipation, hemorrhage, rash, vomiting, decreased appetite, pruritus, and abdominal pain. ( 6.1 ) ZYNYZ as a Single Agent In patients with SCAC, the most common (≥ 10%) adverse reactions are fatigue, musculoskeletal pain, diarrhea, non-urinary tract infections, perineal pain, hemorrhage, urinary tract infection, rash, nausea, decreased appetite, constipation, abdominal pain, dyspnea, pyrexia, vomiting, cough, pruritus, hypothyroidism, headache, and decreased weight. ( 6.1 ) In patients with MCC, the most common (≥ 10%) adverse reactions are musculoskeletal pain, fatigue, pruritus, diarrhea, rash, pyrexia, nausea, and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Incyte Corporation at 1-855-463-3463 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse…
Who shouldn’t take retifanlimab-dlwr
None. None. ( 4 )
Every retifanlimab-dlwr product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Zynyz.
Related calculators
Frequently asked questions
What is retifanlimab-dlwr?
Zynyz (Retifanlimab-Dlwr) is a medication used to treat Merkel Cell Carcinoma.
Can you take retifanlimab-dlwr with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run retifanlimab-dlwr against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does retifanlimab-dlwr come in?
Across the brands we track, retifanlimab-dlwr is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic retifanlimab-dlwr?
We do not currently list a generic-labelled retifanlimab-dlwr product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Retifanlimab-Dlwr: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/retifanlimab-dlwr
- MLA
- “Retifanlimab-Dlwr: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/retifanlimab-dlwr.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for retifanlimab-dlwr on DailyMed (NIH) ↗.